Phase 2 N=4 Miltefosine to Treat Mucocutaneous Leishmaniasis
Mucosal Leishmaniasis · Cutaneous Leishmaniasis
Primary: Number of Participants With Clinical Cure of Lesions — 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=414 Sodium Stibogluconate Treatment of Leishmaniasis
Leishmaniasis
Primary: The Primary Safety Endpoint - Frequency of Complications of Therapy — 414 participants
Phase 2 N=45 A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis
Cutaneous Leishmaniasis
Primary: Date of Clinical Cure — 2; 2; 15; 10 participants
Phase 2 N=92 Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World
Cutaneous Leishmaniasis
Primary: Complete Clinical Response (CCR) of Lesion at Days 50, 100 and 180 (+7 Days) — 47; 30; 3; 12 Participants
Phase 2 N=77 Use of Sodium Stibogluconate as a Treatment for Leishmaniasis
Leishmaniasis
Primary: Number of Participants That Discontinued Due to Adverse Experience, by Type of Adverse Experience — 12; 10; 3; 1 Participants
Phase 2 N=131 Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
Cutaneous T Cell Lymphoma · Peripheral T Cell Lymphoma
Primary: Number of Participants With a Response — 17; 28; 8; 5 participants
Phase 2 N=30 Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama
Leishmaniasis, Cutaneous
Primary: Number of Participants Who Obtained Final Clinical Cure of Index Lesion — 9; 13 Participants
Phase 3 N=437 Efficacy and Safety of Miltefosine or Thermotherapy for Cutaneous Leishmaniasis in Colombia.
Cutaneous Leishmaniasis
Primary: Complete Clinical Response — 85; 103; 86 participants
Phase 2 N=30 Safety, Efficacy and Pharmacokinetics (PK) Study of WR 279,396 Versus Paromomycin for Treatment of Cutaneous Leishmaniasis (Peru-PK)
Leishmaniasis, Cutaneous
Primary: Final Clinical Cure for Index Lesions — 11; 9 participants
Phase 2 N=56 Local Heat Therapy Versus Sodium Stibogluconate for the Treatment of Cutaneous Leishmaniasis
Cutaneous Leishmaniasis
Primary: Equivalence of Efficacy Assessed by the Number of Participants With Clinical Cure — 22; 18; 5; 9 Participants
Phase 2 N=18 Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin
Cutaneous Leiomyomas · Hereditary Leiomyomatosis and Renal Cell Cancer
Primary: Change in Worst Lesional Pain in the Past Week Based on Brief Pain Inventory — -2.50; -1.26 units on a scale
N/A N=41 A Research Study to Examine Cutaneous Allodynia and Cluster Headache
Cluster Headache
Primary: Prevalence of Allodynia in Subjects With Cluster Headache — 20 participants
Phase 2 N=37 Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma
Lymphoma
Primary: Median Progression-free Survival — 5 months
Phase 2 N=8 Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis
Dermatomyositis, Adult Type
Primary: The Primary Endpoint Analysis Would be Overall Response Rate Measured by the Number of Participants Experiencing at Least 4 Points Decrease in CDASI Activity Score at 3…
Phase 2 N=264 Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus · Active Cutaneous Lupus Erythematosus
Primary: Part A: Change From Baseline in Active Joint Count (28-joint Assessment) to Week 24 — -12.7; -9.0; -13.0; -14.5 joints — p=0.037